Peptilogics develops therapeutics to treat and prevent infections related to orthopedic and other devices.
“Infection is the most significant, unsolved problem in orthopedics, and I’ve spent my career watching surgeons challenged to address them and the persistent biofilm with the tools available. Devices alone aren’t going to solve this,” Czartoski said in a press release. “Peptilogics is the first group I’ve seen approaching the root cause with a drug designed specifically for it, and I wanted to be part of what comes next.”
Czartoski spent 22 years at DePuy Synthes, leading the U.S. orthopedics business. Most recently, he served as president of U.S. Surgical and Global R&D at Enovis. He received his M.S. in technology management from Columbia University, MBA from the University of Notre Dame and his B.S. from Ohio State University.
“The only real tool surgeons have had against device-related infections is more surgery. We are aiming to change that with zaloganan, and Tim is going to help us change it,” CEO Jonathan Steckbeck said in a press release. “He’s led billion-dollar launches at the largest orthopedic companies in the world, and he knows what it takes to change surgical practice. As we move forward, his commercial experience, instincts and relationships will be invaluable.”
Peptilogics’ investigational drug, zaloganan, for the treatment of prosthetic joint infections enrolled the first patient in a Phase 2/3 registration trial in March of this year, after raising $78 million to advance the drug into that trial.
The company is also investigating zaloganan for fracture/trauma infections, spine infections and medical device infections. It also lists a controlled-release version of the drug on its website, which is in preclinical trials for the prevention of fracture/trauma infections and medical device infections.
